Consequently, ZEB2 expression may serve as a prognostic biomarker in LSC, alongside E-cadherin, which acts as an EMT biomarker reflecting oncogenesis, tumor development, and metastasis of LSC. This evidence concerns the gene ZEB2 and neoplasm.